Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Attention-Deficit/Hyperactivity Disorder (ADHD)

    Boston, MA

    Search
    Attention-Deficit/Hyperactivity Disorder (ADHD)
    Boston, MA
    Show Map
    Map View
    Boston, MA
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      105 Attention-Deficit/Hyperactivity Disorder (ADHD) Trials near Boston, MA

      Power is an online platform that helps thousands of Attention-Deficit/Hyperactivity Disorder (ADHD) patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      NRCT-101SR for ADHD

      Boston, Massachusetts
      To evaluate the efficacy and safety of NRCT-101SR compared to placebo in subjects 13-17 years of age with ADHD
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3
      Age:13 - 17

      Key Eligibility Criteria

      Disqualifiers:Severe Psychiatric Symptoms, Seizures, Substance Abuse, Others

      160 Participants Needed

      SPN-812 for ADHD

      Boston, Massachusetts
      This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:48 - 69

      Key Eligibility Criteria

      Disqualifiers:Major Psychiatric, Neurological Disorders, Others
      Must Not Be Taking:CYP1A2 Substrates

      286 Participants Needed

      NRCT-101SR + NRCT-202XR for ADHD

      Boston, Massachusetts
      A combination therapy of NRCT-101 with NRCT-202 is being developed for patients with ADHD.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:13 - 17

      Key Eligibility Criteria

      Disqualifiers:Non-ADHD, Non-English, Others
      Must Be Taking:ADHD Medication

      60 Participants Needed

      Guided Deep Breathing for ADHD

      Brookline, Massachusetts
      Attention-deficit/hyperactivity disorder (ADHD) affects approximately 11% of children and adolescents in the United States. Individuals with ADHD experience substantial impairments and burdens across multiple areas of daily living, including peer difficulties, academic difficulties, poor job outcomes, high rates of co-occurring disorders, and large financial costs. Although there are many well-established, evidence-based treatments for ADHD, many children continue to experience significant impairment and elevated ADHD symptoms even with prolonged treatment. Further, there are several limitations to existing treatment approaches, including medication side effects, difficulty accessing behavioral treatments, and high out-of-pocket costs for behavioral treatments. Thus, there is a crucial need to identify low cost, low burden, alternative or additive intervention approaches for pediatric ADHD. In the current pilot study, we aim to evaluate responses in behavioral and brain-based markers of attention to a mindfulness-based intervention. Mindfulness-based interventions (MBIs), including deep breathing, have received considerable research attention regarding their benefits for ADHD symptoms. Deep breathing is a strong candidate as a supplementary MBI intervention for children with ADHD due to its simplistic and easy-to-implement nature. Studies examining the effects of deep breathing on physiological arousal and ADHD symptoms in children have yielded promising results. Children will be led through a brief deep breathing intervention using a novel tool designed to optimize child engagement in deep breathing. This tool, Domi, is designed to be held in the child's hands and uses a series of haptic vibrations to provide real-time deep breathing pacing guidance. We predict that following a brief deep breathing practice, children with ADHD will demonstrate improved sustained attention, reaction time consistency, and inhibitory control. These areas of attention and behavioral functioning will be assessed using computer tasks and measures of brain activity. We plan to use the results of this study to strengthen a future application for grant funding to run a similar trial with many more children. We believe that the results of this and future studies will improve the lives of children with ADHD and their families.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Age:7 - 11

      Key Eligibility Criteria

      Disqualifiers:Intellectual Disability, Autism, Hearing Impairments, Others
      Must Not Be Taking:Non-stimulants

      10 Participants Needed

      tRNS for ADHD

      Boston, Massachusetts
      A randomized, sham-controlled, double-blind clinical trial to examine the safety and effectiveness of tRNS on unmedicated pediatric patients (7-12 years) with ADHD. Subjects will undergo either tRNS or sham treatment for 10 days during a two-week period in a home-simulated environment. Each treatment session is 20 minutes, during which their attention will be maintained using a software game.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:7 - 12

      Key Eligibility Criteria

      Disqualifiers:Severe ODD, Bipolar, Substance Abuse, Others
      Must Not Be Taking:ADHD Medications

      146 Participants Needed

      tDCS for ADHD

      Charlestown, Massachusetts
      This trial is testing if home-based tDCS can help people with ADHD by using a small electrical current to improve brain function. It aims to make advanced treatments more accessible by allowing patients to use the therapy at home. Transcranial direct current stimulation (tDCS) has been studied for its potential to improve cognitive functions in ADHD, showing promise in enhancing attention, inhibitory control, and working memory.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Epilepsy, Pregnancy, Substance Dependence, Others

      60 Participants Needed

      Brain Stimulation for ADHD

      Boston, Massachusetts
      This trial is testing mild electrical brain stimulation to see how it affects brain function and thinking skills in people who might benefit from improved cognitive abilities.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Epilepsy, Metallic Implants, Pregnancy, Others
      Must Not Be Taking:Psychotropic Medications

      104 Participants Needed

      CenteringParenting for Childhood Development

      Boston, Massachusetts
      Disparities in health begin in early childhood. Early life experiences influence brain development and have significant implications on future health and developmental outcomes. Low-income children are at greater risk of developmental delays in large part due to a lack of an enriched environment. Disparities in early childhood development increase risk for stunted academic achievement throughout the life course. Primary care is a universal exposure in early childhood and therefore is also a significant entry point for promoting optimal child development. There is a need to provide effective, low-cost, and scalable interventions in primary care to support early childhood development.The CenteringParenting intervention is designed to reduce negative health and developmental outcomes within a model of group routine child health care. To date, there is no evidence of the benefits of the CenteringParenting intervention on school readiness, or improvements in parental behaviors that support optimal developmental milestones and achievement. The intent of this study is to determine the effectiveness of the CenteringParenting intervention on school readiness in early childhood, as measured by language development at 24 months, (in addition to health care utilization, child routine care maintenance, parenting stress, caregiver behaviors and attitudes).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:< 3

      Key Eligibility Criteria

      Disqualifiers:Preterm Birth, Chronic Conditions, Others

      1200 Participants Needed

      Resiliency Programming for Caregivers of Children with Learning Disabilities

      Boston, Massachusetts
      This is a randomized open pilot trial enrolling up to 40 co-primary caregivers of children with LAD. Participants will be randomized to receive either mind-body resiliency group (SMART-LAD, intervention) or an evidence-based group intervention Health Education Program (HEP, control) which is a multiple behavior change program that addresses sleep, exercise, nutrition, substance use, and working with one's healthcare team. Both the SMART-3RP and HEP programs have been modified based on adaptions from our previous qualitative study.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Psychiatric Conditions, Others

      40 Participants Needed

      Quillivant XR for ADHD in Down Syndrome

      Boston, Massachusetts
      Children with Down syndrome (DS) have a 3-5 time greater prevalence of Attention Deficit Hyperactivity Disorder (ADHD) than typically developing (TD) children. Despite this higher risk of ADHD, rates of stimulant medication treatment are disproportionately low in children with DS+ADHD, even though stimulants are the most efficacious ADHD treatment and are recommended by consensus guidelines for use in children with intellectual disability and ADHD. The investigators propose the first randomized clinical trial (RCT) of stimulant medication in children with DS+ADHD. This RCT may provide evidence regarding the short- and long-term safety and efficacy of stimulant use in children with DS+ADHD, both with and without CHD. All children enrolled in the study will complete a comprehensive assessment battery evaluating ADHD diagnostic criteria, as well as behavioral, cognitive, academic, and functional impairments.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:6 - 17

      Key Eligibility Criteria

      Disqualifiers:Psychoses, Bipolar, Organic Brain Injury, Heart Conditions, Severe OSA, Pregnancy, Others
      Must Not Be Taking:ADHD Stimulants, MAOIs

      100 Participants Needed

      Adderall XR for ADHD

      Boston, Massachusetts
      The investigators are conducting a 10-week brain imaging and medication study. They are doing the research to study the response of Attention-Deficit/ Hyperactivity Disorder (ADHD) in youth with Autism Spectrum Disorder (ASD) on extended-release formulation of mixed amphetamine salts (MAS) (also know as Adderall XR). The investigators also want to find out if taking MAS has any effect on the brains of children and adolescents with ADHD and ASD. This study will help researchers better understand how the use of MAS to treat ADHD effects children and adolescents with ASD. The investigators will compare MAS to a placebo. The placebo will look exactly like the MAS capsules but will contain no MAS. During this study, participants may get a placebo instead of MAS. Placebos are used in research studies to see if the study results are due to the study drug or due to other reasons. Participants with ASD and ADHD will complete 4-weeks of treatment with the study medication or placebo. They will complete bi-weekly study visits virtually via a telemedicine platform with the study doctor and complete questionnaires. On alternating weeks, they will meet with a Massachusetts General Hospital (MGH) study team member to discuss medication adherence and potential side effects. Participants will have the option to attend all study visits in-person if participants prefer. They will also complete baseline and endpoint Magnetic Resonance (MR) scan visits at Massachusetts Institute of Technology (MIT). During the MR Scan visits, they will complete a series of tasks to measure inattention, impulsivity, reward sensitivity, decision-making, and working memory. Participants without ADHD or ASD will complete eligibility screening with MGH. If eligible, they will be invited to baseline and endpoint MR scan visits at MIT. During the MR Scan visits, they will complete a series of tasks to measure inattention, impulsivity, reward sensitivity, decision-making, and working memory.

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 4
      Age:8 - 18

      Key Eligibility Criteria

      Disqualifiers:Intellectual Disability, Cardiac Disease, Seizures, Others
      Must Be Taking:Non-stimulant ADHD Treatment

      196 Participants Needed

      Stimulant Medications for ADHD in Autism Spectrum Disorder

      Boston, Massachusetts
      This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents with autism. Using a sequential, multiple assignment randomization trial (SMART) design the study will not only assess these two medications but also the role of an increasingly popular class of ADHD medication, the alpha-2 agonists. Findings from this study will help improve clinicians' approach to medication selection and reduce the repeated trials of multiple medications that are current standard care.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:4 - 17

      Key Eligibility Criteria

      Disqualifiers:Unstable Medications, Others
      Must Not Be Taking:ADHD Medications

      500 Participants Needed

      PRE-CARE Intervention for ADHD in Preschoolers

      Boston, Massachusetts
      The goal of this proposed study is to pilot test a novel treatment model (PRE-CARE) addressing unmet social needs for families of preschool-age children with Attention Deficit/Hyperactivity Disorder (ADHD) symptoms. The investigators will conduct an adaptive, pilot randomized controlled trial (RCT) of the intervention with parents of 60 low-income children age 3-5 (36-71 months) with ADHD symptoms in order to: optimize intervention delivery; field test study logistics (e.g., recruitment, enrollment, randomization, retention); explore putative intervention mechanisms; and obtain estimates of study parameters to plan an appropriately powered RCT of the intervention. The PRE-CARE intervention is adapted from Well Child Care, Evaluation, Community, Resources, Advocacy, Referral, Education (WE CARE), a screening and referral intervention that has been shown to be feasible and effective in addressing the family psychosocial stressors of low-income families seen in pediatric medical homes. Given the negative impact that socioeconomic stressors can have on the health and development of young children with ADHD symptoms, tailored interventions such as PRE-CARE may serve as a vital early intervention strategy to promote long-term well-being.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Age:16+

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      55 Participants Needed

      Electrical Stimulation for Depression

      Boston, Massachusetts
      In the current study, the investigators aim to understand the role of transcranial direct current stimulation (tDCS) in improving executive function across neuropsychiatric populations known to have deficits in this cognitive domain.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Epilepsy, Metallic Implants, Pregnancy, Others
      Must Not Be Taking:Psychotropic Medications

      600 Participants Needed

      Cognitive Behavioral Therapy for Depression

      Boston, Massachusetts
      To examine the effectiveness and clinical care outcomes of cognitive-behavioral therapy interventions at Massachusetts General Hospital (MGH).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Active Suicidality, Untreated Bipolar, Psychosis, Others

      250 Participants Needed

      Executive Function Training for ADHD

      Boston, Massachusetts
      The goal of this clinical trial is to evaluate how different approaches to executive function (like adding game-like features, varying the number of tasks, and providing coaching) can enhance executive function outcomes in adolescents with and without ADHD. The main questions it aims to answer are: * What components of executive function training contribute most to improving outcomes? * How do training components vary in their impacts on adolescents diagnosed with ADHD compared to those without a diagnosis? * What individual characteristics influence the effectiveness of executive function training? Researchers will test six different training setups to examine which setups are the most effective for different people. They will evaluate both how well participants follow the training schedule and whether there are changes in psychological and cognitive outcomes after training. Participants will complete: * 40 training sessions over 4 weeks * A set of tests and surveys before and after the training * Follow-up assessments and surveys 6 months after finishing the training
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Age:12 - 17

      Key Eligibility Criteria

      Disqualifiers:Intellectual Disability, Autism, Psychosis, Others
      Must Not Be Taking:ADHD Medication

      780 Participants Needed

      Intermittent Theta Burst Stimulation for ADHD

      East Providence, Rhode Island
      The objective of this project is to examine the differential therapeutic effect of intermittent theta burst stimulation (iTBS; a type of repetitive transcranial magnetic stimulation) to the left DLPFC versus right PreSMA in modulating working memory (WM) versus inhibitory control (IC) deficits. Fifty adolescents (12-18 years old) with parent-reported WM and IC deficits and diagnosed ADHD will be randomized to DLPFC or PreSMA targeted 3x-daily iTBS for a total of ten days (30 total sessions).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:12 - 18

      Key Eligibility Criteria

      Disqualifiers:Epilepsy, Seizures, Substance Abuse, Others
      Must Not Be Taking:Seizure Threshold-lowering Drugs

      50 Participants Needed

      Brain Stimulation for ADHD

      East Providence, Rhode Island
      This trial tests if a device that sends small electrical pulses to the brain can help teenagers with ADHD improve their memory and attention. The treatment targets a specific brain area to make brain waves work better together.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:12 - 18

      Key Eligibility Criteria

      Disqualifiers:Epilepsy, Seizures, Substance Abuse, Others
      Must Not Be Taking:Seizure Threshold Reducers

      25 Participants Needed

      Task Practice Interventions for Executive Function

      Providence, Rhode Island
      The goal of this basic experimental clinical trial is to understand the effect of multitasking practice on the structure of neural representations of tasks in the human lateral prefrontal cortex and control brain regions. The main question it aims to answer is: What changes in neural representational structure predict improvements in multitasking behavior due to multitasking practice? Healthy human participants will learn two independent tasks, each mapping a set of stimuli to motor responses based on different rules. Participants will be randomized to one of two interventions. Participants assigned to the multitask practice intervention (MPI) will practice multitasking the two tasks over multiple days. Those assigned to the single-task practice intervention (SPI) will instead practice each task separately while controlling for the total number of practice opportunities associated with each task across the interventions. Both before and after the practice, the ability of all participants to perform both tasks simultaneously will be behaviorally measured using a well-established psychological refractory period (PRP) paradigm, and their neural representations will be measured using functional MRI while they perform the two tasks. Researchers will then compare improvements in multitasking behavior across the two groups, as well as changes in neural representational geometry of the tasks in the lateral prefrontal cortex and control brain regions, and test whether multitasking training is associated with specific changes in neural representations in the lateral prefrontal cortex.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 35

      Key Eligibility Criteria

      Disqualifiers:Neurological, Psychiatric, Pregnancy, Implants, Others
      Must Not Be Taking:Brain Related Medications

      60 Participants Needed

      Centanafadine for ADHD

      East Greenwich, Rhode Island
      This trial aims to test the safety and tolerability of a daily ADHD medication in children and teens aged 4-17. The medication releases its effects slowly over the day to help manage symptoms consistently. HLD200 is a form of methylphenidate designed to provide benefits from morning until evening.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:4 - 18

      Key Eligibility Criteria

      Disqualifiers:Tourette's, Severe Anxiety, Psychosis, Autism, MDD, Others

      680 Participants Needed

      Why Other Patients Applied

      "I have been living with untreated ADHD my entire life life. It’s getting to the point where most days can be quite debilitating and I experience adhd paralysis on a regular basis. My PCP won’t even listen to my concerns and I don’t know where to turn to get help. Hoping to get better care this way."

      VN
      ADHD PatientAge: 49

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I am currently taking Mydayis. I've used vyvanse, adderall, strattera, concerta. I have struggled with this disorder my whole life. At 43, I am attempting to go to law school. I would like to have a different experience than I had in undergrad. I suffer from poor executive dysfunction. Impulsively, and lack of focus. ADHD has impacted every part of my life. "

      LX
      ADHD PatientAge: 44

      "ADHD has been a trait that I consider as a blessing, as it can make me more creative, but I struggle with focusing and forgetting things... it affects my work. Looking for a new medicine to try will hopefully help me to get better along with my day-to-day activities and job."

      QM
      ADHD PatientAge: 27

      "Executive function difficulties impact my daily life, and I have not found relief through traditional approaches. I dislike how standard stimulants make me feel. I'm very interested in trying the latest research treatments."

      FF
      ADHD PatientAge: 35
      Match to a Attention-Deficit/Hyperactivity Disorder (ADHD) Trial

      EWM Training for ADHD

      Hartford, Connecticut
      The proposed study will replicate target engagement as assessed in the first phase while also determining if it correlates with clinically meaningful improvements in ADHD dysfunction

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:12 - 18

      Key Eligibility Criteria

      Disqualifiers:Psychosis, Bipolar, ASD, Others

      130 Participants Needed

      Stimulant vs Non-stimulant Treatments for ADHD

      New York, New York
      The study team will examine the effects of FDA approved stimulant and non-stimulant medications for ADHD, among youth with ADHD and with and without Oppositional Defiant Disorder (ODD) or Conduct Disorder (CD), on reward systems of the brain using fMRI.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:7 - 12

      Key Eligibility Criteria

      Disqualifiers:Neurological Illness, Head Injury, Psychiatric Disorder, Others
      Must Not Be Taking:Stimulants

      44 Participants Needed

      Methylphenidate for ADHD

      New York, New York
      This trial is investigating how genetic differences in an enzyme called CES1 affect the way ADHD patients respond to the medication methylphenidate. The goal is to understand why some patients do not respond well or experience severe side effects. Methylphenidate (MPH) is a well-established treatment for ADHD, but not all patients respond to it, and some experience adverse reactions.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:6 - 17

      Key Eligibility Criteria

      Disqualifiers:Non-ADHD, Smokers, Pregnant, Others
      Must Be Taking:Methylphenidate

      500 Participants Needed

      Jornay PM for ADHD

      New York, New York
      The goal of this study is to extend the efficacy evidence of sustained release methylphenidate compound (JornayPM) in adults with Attention-deficit/hyperactivity disorder (ADHD). JornayPM has recently been approved for treatment of patients 6 years and older with ADHD; the release mechanism is unique among ADHD products in that it is taken in the evening, with effects in the morning upon awakening and then throughout the subsequent day. Of note, to date, there is no clinical data as to the tolerability or clinical effects or dosing in adults with ADHD; therefore the primary aim of this trial is to gather the first set of these data.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Psychotic Disorders, Autism, Others
      Must Not Be Taking:MAOIs, Benzodiazepines, Antipsychotics, Others

      30 Participants Needed

      Diagnostic Algorithm for ADHD

      New York, New York
      This study aims to demonstrate the accuracy of the MT1 algorithm using the MindTension biometric sensor device as a diagnostic aid for healthcare providers in diagnosing ADHD in youth ages ≥ 6 to ≤17 years.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:6 - 17

      Key Eligibility Criteria

      Disqualifiers:Seizure Disorder, IQ<70, PTSD, Others
      Must Not Be Taking:Psychotropics

      120 Participants Needed

      Centanafadine for ADHD

      New York, New York
      This trial will test if centanafadine, a daily extended-release medication, can help children aged 4 to 12 years with ADHD by balancing brain chemicals to improve focus and reduce hyperactivity. Centanafadine is being investigated for the treatment of ADHD.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Age:4 - 12

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      574 Participants Needed

      SPN-812 for ADHD

      New York, New York
      Open label, flexible dose, decentralized clinical trial evaluating the efficacy and safety of SPN-812 in adults with ADHD and mood symptoms.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      750 Participants Needed

      Guanfacine + Mindfulness for Opioid Use Disorder

      Newark, New Jersey
      The US is currently going through an opioid crisis, and while Medication Assisted Treatments such as buprenorphine (BUP) have proved highly effective at stabilizing the neurobiology underlying acute withdrawal, they have been less effective at preventing longer-term relapse and adherence. This may be due to the fact that they do not fully engage the neural processes sub-serving the emotional control of sensitized negative mood and reward sensitivity during stress- and opioid-cue provocation, respectively. In contrast while the alpha2 agonist, guanfacine, may attenuate stress-provoked opioid craving by mediating top-down prefrontal control over sensitized dysphoria, the behavioral intervention, Mindfulness Oriented Recovery Enhancement (MORE) may reduce opioid cue-provoked craving by mediating top-down prefrontal control over hedonic dysregulation. Furthermore, while both interventions separately may prove effective as longer-term adjunctive therapies, they may offer greater efficacy together, providing a unique medication/behavioral combination able to target both stress and reward provocation mechanisms. To optimally test this hypothesis, a staged approach is proposed to first confirm the efficacy of both GXR and MORE, independently and combined (R61), prior to elucidating underlying neural mechanisms (R33). Using a 2 X 2 design, N=80 OUD individuals on BUP will be randomized to either 6-weeks of Guanfacine extended release (GXR; 3mgs, n=40) or placebo (PBO; n=40). Half of all participants in each group will then receive either weekly MORE, or a Support Group (SG) control, creating four intervention groups (Control Grp: PBO+SG, n=20); (GXR Grp: GXR+SG, n=20); (MORE Grp: PBO+ MORE, n=20); (Combined Grp: GXR+MORE, n=20). A pre- and post-laboratory study will be conducted before and after six weeks of intervention where participants will be randomly exposed to 3 personalized guided imageries (stress, opioid cue, neutral). Subjective measures of opioid craving, anxiety, mood, stress, emotional reappraisal, and heart rate will be collected before and after imagery exposure. Following milestone completion, an identical design is proposed in N=144 individuals, where participants will be exposed to imageries in the MRI scanner (R33). On the basis of prior research, it is hypothesized in that GXR will attenuate opioid craving and improve emotion regulation during stress, while MORE will demonstrate the same effects during opioid cue exposure. Combined GXR and MORE will also demonstrate additive or synergistic improvements compared with each intervention alone (R61). The effects of GXR on opioid cue- and MORE on stress-provoked opioid seeking will be explored. In the R33 component, it is hypothesized that GXR will improve regulatory and affective brain function during stress, and MORE will improve regulatory and reward function during opioid cue exposure. Combined GXR and MORE may improve regulatory function in an additive or synergistic manner (R33). Findings will help elucidate the efficacy and neural mechanisms underpinning a novel integrated pharmaco-behavioral therapy for OUD individuals maintained on BUP.
      Stay on current meds
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Severe Substance Use, Psychotic, Hypotensive, Pregnant, Others
      Must Be Taking:Buprenorphine

      224 Participants Needed

      Virtual Reality for ADHD

      Piscataway, New Jersey
      The goal of this pilot randomized clinical trial is to test the impact of a virtual reality program for improving the ability of emerging adults (age 18-25) with attention deficit hyperactivity disorder (ADHD) to stay focused while completing homework and studying. This study compares the impact of using a virtual reality headset to using a virtual reality headset while also receiving feedback about levels of focus to a control group. The main question is whether participants demonstrate significantly improved concentration while completing homework and studying in virtual reality and whether they enjoy and prefer working in a virtual reality environment. Concentration is measured both through participant report and also using keyboard and mouse click data to assess work productivity objectively.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 25

      Key Eligibility Criteria

      Disqualifiers:Autism, Bipolar, OCD, Seizures, Others

      45 Participants Needed

      Virtual Reality for ADHD

      New Brunswick, New Jersey
      The goal of this larger parallel group randomized trial is to test the impact of a virtual reality program for improving the ability of emerging adults (age 18-25) with attention deficit hyperactivity disorder (ADHD) to stay focused while completing homework and studying. This study compares the impact of using a virtual reality headset to using a virtual reality headset while also receiving feedback about levels of focus to a control group. The main question is whether participants demonstrate significantly improved concentration while completing homework and studying in virtual reality and whether they enjoy and prefer working in a virtual reality environment. Concentration is measured both through participant report and also using keyboard and mouse click data to assess work productivity objectively.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 4
      Age:18 - 25

      Key Eligibility Criteria

      Disqualifiers:Autism, Bipolar, OCD, Substance Abuse, Others

      252 Participants Needed

      1234

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Attention-Deficit/Hyperactivity Disorder (ADHD) clinical trials in Boston, MA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Attention-Deficit/Hyperactivity Disorder (ADHD) clinical trials in Boston, MA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Attention-Deficit/Hyperactivity Disorder (ADHD) trials in Boston, MA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Boston, MA for Attention-Deficit/Hyperactivity Disorder (ADHD) is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Boston, MA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Attention-Deficit/Hyperactivity Disorder (ADHD) medical study in Boston, MA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Attention-Deficit/Hyperactivity Disorder (ADHD) clinical trials in Boston, MA?

      Most recently, we added Iron Supplementation for ADHD and Restless Sleep, MomMA Intervention for ADHD and Atomoxetine for PTSD to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in Massachusetts

      Anxiety Clinical Trials in Massachusetts

      Schizophrenia Clinical Trials in Massachusetts

      ADHD Clinical Trials in Massachusetts

      Bipolar Disorder Clinical Trials in Massachusetts

      Multiple Sclerosis Clinical Trials in Massachusetts

      Autism Clinical Trials in Massachusetts

      Treatment Resistant Depression Clinical Trials in Massachusetts

      Borderline Personality Disorder Clinical Trials in Massachusetts

      Social Anxiety Disorder Clinical Trials in Massachusetts

      Parkinson's Disease Clinical Trials in Massachusetts

      Alzheimer's Disease Clinical Trials in Massachusetts

      By Location

      Clinical Trials near Boston, MA

      Clinical Trials near Worcester, MA

      Clinical Trials near Springfield, MA

      Clinical Trials near Burlington, MA

      Clinical Trials near Fall River, MA

      Clinical Trials near Cambridge, MA

      Clinical Trials near North Dartmouth, MA

      Clinical Trials near Newton, MA

      Clinical Trials near Waltham, MA

      Clinical Trials near Watertown, MA

      Clinical Trials near Belmont, MA

      Clinical Trials near Brockton, MA

      Other People Viewed

      By Subject

      12 Attention-Deficit/Hyperactivity Disorder (ADHD) Trials near Baltimore, MD

      15 Attention-Deficit/Hyperactivity Disorder (ADHD) Trials near Albuquerque, NM

      Top Attention-Deficit/Hyperactivity Disorder (ADHD) Clinical Trials near San Diego, CA

      13 Attention-Deficit/Hyperactivity Disorder (ADHD) Trials near Cincinnati, OH

      14 Attention-Deficit/Hyperactivity Disorder (ADHD) Trials near Anaheim, CA

      72 Attention-Deficit/Hyperactivity Disorder (ADHD) Trials near Miami, FL

      14 Attention-Deficit/Hyperactivity Disorder (ADHD) Trials near Los Angeles, CA

      Top Attention-Deficit/Hyperactivity Disorder (ADHD) Clinical Trials near Tampa, FL

      Top Attention-Deficit/Hyperactivity Disorder (ADHD) Clinical Trials near Long Beach, CA

      Top Depression Clinical Trials near Boston, MA

      Top Psoriasis Clinical Trials near Boston, MA

      Top Social Anxiety Disorder Clinical Trials

      By Trial

      MomMA Intervention for ADHD

      Jornay PM for ADHD

      Parent-Educator Action Response for ADHD

      Atomoxetine for PTSD

      EB-1020 for ADHD

      Wearable Digital Therapy for ADHD

      Intermittent Theta Burst Stimulation for ADHD

      Mindful Attention Training for Pediatric Cancer Survivors

      Visual Tasks for Attention Deficit Disorder

      VR Training for Hemispatial Neglect

      Digital Therapy Apps for Childhood Behavior Problems

      Cognitive Training for PTSD

      Related Searches

      Top Alzheimers-disease Clinical Trials near Phoenix, AZ

      Top Pathology Clinical Trials

      Top Liver-transplant Clinical Trials

      AZD9291 for Non-Small Cell Lung Cancer

      Tailored Advice Tool for Weight Loss

      Near-infrared Light Therapy for Brain Aging

      Intralesional Nivolumab for Precancerous Conditions

      Neuro Device for Aphasia

      Mezagitamab for Kidney Disease

      TRRP for Traumatic Injury in Adolescents

      Exergaming for Head and Neck Cancer

      MDI-2517 for Safety and Tolerability